CG Oncology (CG Oncology) Receivables Turnover : 0.00 (As of Mar. 2024)

View and export this data going back to 2024. Start your Free Trial

What is CG Oncology Receivables Turnover?

The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. CG Oncology's Revenue for the three months ended in Mar. 2024 was $0.53 Mil. CG Oncology's average Accounts Receivable for the three months ended in Mar. 2024 was $0.00 Mil.

CG Oncology Receivables Turnover Historical Data

The historical data trend for CG Oncology's Receivables Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CG Oncology Receivables Turnover Chart

CG Oncology Annual Data

Trend

Dec21

Dec22

Dec23

Receivables Turnover

CG Oncology Quarterly Data
	Dec21	Sep22	Dec22	Mar23	Sep23	Dec23	Mar24
Receivables Turnover	Get a 7-Day Free Trial			-	-	-	-	-

Competitive Comparison of CG Oncology's Receivables Turnover

For the Biotechnology subindustry, CG Oncology's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

CG Oncology's Receivables Turnover Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CG Oncology's Receivables Turnover distribution charts can be found below:

* The bar in red indicates where CG Oncology's Receivables Turnover falls into.

CG Oncology Receivables Turnover Calculation

Receivables Turnover measures the number of times a company collects its average accounts receivable balance.

CG Oncology's Receivables Turnover for the fiscal year that ended in Dec. 2023 is calculated as

	Receivables Turnover (A: Dec. 2023 )
=	Revenue	/	Average Total Inventories
=	Revenue (A: Dec. 2023 )	/ (	(Accounts Receivable (A: Dec. 2022 )	+	Accounts Receivable (A: Dec. 2023 ))	/	count )
=	0.204	/ (	(0	+	0)	/	1 )
=	0.204	/	0
=	N/A

CG Oncology's Receivables Turnover for the quarter that ended in Mar. 2024 is calculated as

	Receivables Turnover (Q: Mar. 2024 )
=	Revenue	/	Average Total Inventories
=	Revenue (Q: Mar. 2024 )	/ (	(Accounts Receivable (Q: Dec. 2023 )	+	Accounts Receivable (Q: Mar. 2024 ))	/	count )
=	0.529	/ (	(0	+	0)	/	1 )
=	0.529	/	0
=	N/A

CG Oncology (NAS:CGON) Receivables Turnover Explanation

An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.

CG Oncology Receivables Turnover Related Terms

Thank you for viewing the detailed overview of CG Oncology's Receivables Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.

CG Oncology (CG Oncology) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CG Oncology Inc (NAS:CGON) » Definitions » Receivables Turnover

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

CG Oncology Inc is a clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. Their product candidate cretostimogene, is initially in clinical development for the treatment of patients with high-risk Non-Muscle Invasive Bladder Cancer who are unresponsive to Bacillus Calmette Guerin (BCG) therapy, the current standard-of-care for high-risk NMIBC.

CG Oncology (CG Oncology) Headlines

From GuruFocus

CG Oncology to Unveil Encouraging Results on Cretostimogene in Combination with Pembrolizumab at ASCO 2024

By Marketwired • 04-24-2024